Get the Stockscreener App
40.64
5.71%
-2.46
Pre-market:
41.70
1.06
+2.61%
Guardant Health Inc stock is traded at $40.64, with a volume of 2.27M.
It is down -5.71% in the last 24 hours and down -13.50% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$43.10
Open:
$42.58
24h Volume:
2.27M
Relative Volume:
1.04
Market Cap:
$5.02B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-9.5849
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+1.17%
1M Performance:
-13.50%
6M Performance:
+51.70%
1Y Performance:
+113.89%
1-Day Range:
$39.72
$42.86
1-Week Range:
$34.88
$45.00
52-Week Range:
$15.81
$50.89
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
40.64 | 5.02B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Raymond James maintains Guardant Health stock at Outperform By Investing.com - Investing.com Canada
Guardant Health gains ADLT status for CRC blood test By Investing.com - Investing.com Canada
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue - Benzinga
Sector Update: Health Care - TradingView
Guardant Health stock up on Medicare ADLT status (GH:NASDAQ) - Seeking Alpha
Guardant Health Shares Soar After Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 11:01 am EDT - Marketscreener.com
Citi maintains Buy on Guardant Health, price target at $60 By Investing.com - Investing.com UK
Guardant Health Receives ADLT Status From CMS for Shield Blood Test - 01Net
Guardant Health Says Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 08:48 am EDT - Marketscreener.com
Guardant Health gains ADLT status for CRC blood test - Investing.com India
Guardant Health Receives ADLT Status From CMS For Shield Blood Test -March 11, 2025 at 07:19 am EDT - Marketscreener.com
When the Price of (GH) Talks, People Listen - Stock Traders Daily
FDA approves blood test for colon cancer detection - MSN
Bank of New York Mellon Corp Reduces Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - Defense World
Principal Financial Group Inc. Has $308,000 Stake in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says - Marketscreener.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Guardant Health, Inc. (NASDAQ:GH) Short Interest Update - Defense World
Lung Cancer Diagnostics Market Growth | Trends, Size & Forecast 2025-2033 | DSS Imagetec, Abbott, Guardant Health. - openPR
Guardant Health director Joyce sells $4,271 in stock - Investing.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight - Investing.com India
Guardant Health director Joyce sells $4,271 in stock By Investing.com - Investing.com UK
Guardant Health price target raised to $52 from $42 at Morgan Stanley - TipRanks
LSUHS partners with Dak Prescott to boost colon cancer screening - KTALnews.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight By Investing.com - Investing.com UK
Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating - Marketscreener.com
Guardant Health at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities - The Bakersfield Californian
Commit To Buy Guardant Health At $32, Earn 17.9% Annualized Using Options - Nasdaq
Guardant Health Financial Report: Q4 2024 Revenue Surpasses ExpectationsNews and Statistics - IndexBox, Inc.
Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue - Yahoo Finance
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Analysts - Defense World
ARK Investment Management LLC Has $43.99 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
(GH) Technical Data - Stock Traders Daily
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change - Yahoo Finance
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Guardant Health (GH): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
Guardant Health Stock Surges Amid Analyst Optimism - TipRanks
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year? - MSN
Guardant Health (NASDAQ:GH) Stock Price Down 6.9% Following Weak Earnings - MarketBeat
Guardant accuses Natera of poaching employees, stealing trade secrets - MedTech Dive
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):